IVF Clinic Success Rates in 2026: How SART Data Gaps, Hospital Financial Instability, and a $15K–$30K Cost Spread Should Change Which Clinic You Choose
You just got a quote: $13,800 for an IVF retrieval cycle. It sounds reasonable. But here's the question nobody asked you during that consultation: does this clinic's live birth rate for your age and diagnosis justify the price — compared to a clinic across town, or two hours away, or in the next state?
Feralyx's analysis of the CDC's ART reporting database — 2,880 rows of clinic-level success rate data across age brackets and diagnoses — shows a live birth rate spread of 20–26 percentage points between the bottom and top quartile of SART-reporting clinics for patients ages 35–40 using their own eggs. For a 38-year-old comparing a 30% per-cycle rate at Clinic A against a 43% rate at Clinic B, the cumulative live birth probability across two cycles is different by roughly 18 percentage points — and so is the total bill. That's what this post is about.
Why SART Data Is Both Your Best Tool and a Known Gaming Target
SART (Society for Assisted Reproductive Technology) publishes annual outcome data for every U.S. fertility clinic, broken down by age, diagnosis, egg source, and cycle type. In theory, this is everything you need. In practice, the data is nearly impossible to use without knowing what to look for — and some clinics know exactly how to present it in the most favorable light.
A recent Tenet Healthcare vs. Leapfrog legal dispute illustrates the pattern precisely. Leapfrog is a nonprofit hospital quality rating organization. Tenet, one of the country's largest for-profit hospital chains, sued Leapfrog over quality ratings it found commercially unflattering. A federal judge dismissed the lawsuit entirely — and Tenet now faces a $10.5 million legal fee demand. The takeaway for fertility patients: large healthcare systems spend serious money fighting transparency initiatives that disadvantage them financially. Private equity-owned fertility clinic networks — which now control a significant and growing share of U.S. clinics — operate with the same incentives at smaller scale.
Two tactics inflate published SART success rates without technically misrepresenting anything:
Selective patient intake. A clinic that screens out patients with very low AMH, advanced age, or severe male factor will naturally report higher success rates than a clinic willing to treat complex cases. This is legal and nearly invisible in aggregate SART data unless you cross-reference patient volume against outcome rates.
Cancellation rate masking. When a retrieval cycle produces poor-quality embryos and the clinic cancels before transfer, that cancellation frequently doesn't appear as a "failed cycle" in headline success rate figures. Only cycles that reached transfer get counted — which artificially inflates the published live birth rate per transfer. As discussed in our analysis of IVF clinic SART data, cancellation rates, and cost gaps, the cancellation rate is one of the most revealing numbers in the full SART data table — and most patients never pull it.
This is the kind of side-by-side analysis Feralyx was built to run — pulling live birth rates per retrieval (not per transfer), cancellation rates, and diagnosis-specific outcomes into a comparison you can actually use before signing a financial agreement.
The Cost Spread: Same Protocol, $10K–$28K Different Outcome
The success rate conversation is inseparable from cost. Based on Feralyx's ivf_costs dataset (600 rows of clinic-level pricing data sourced from FertilityIQ), a quoted retrieval cycle of $12,000–$16,000 routinely becomes $26,000–$41,000 all-in once you add every line item you'll actually encounter:
| Cost Component | Low Estimate | High Estimate |
|---|---|---|
| Base retrieval cycle | $12,000 | $16,000 |
| Injectable medications | $4,500 | $8,000 |
| PGT-A (preimplantation genetic testing) | $3,500 | $6,000 |
| Monitoring (bloodwork + ultrasounds) | $1,500 | $3,500 |
| Frozen embryo transfer (FET) | $3,500 | $6,000 |
| Embryo storage (year 1) | $500 | $1,200 |
| Total (1 retrieval + FET) | $25,500 | $40,700 |
The medication line is where most patients get blindsided. Our medication_costs dataset (240 rows) shows per-cycle injectable drug costs ranging from $3,800 to $9,500 depending on protocol, stimulation response, and whether you're paying retail or accessing specialty pharmacy partnerships. A high-stimulation protocol at a clinic that doesn't actively manage medication costs can add $3,000–$4,000 compared to a clinic with integrated pharmacy programs — on top of an already-wide base cycle price gap.
A Worked Comparison: Clinic A vs. Clinic B at Age 38
Here's how the numbers actually stack up. Using Feralyx's cdc_art_ivf_success_rates data and ivf_costs modeling, here's a realistic side-by-side for a 38-year-old patient with diminished ovarian reserve (low AMH) planning up to three cycles with PGT-A:
Clinic A (median SART performer, higher pricing):
- Live birth rate per retrieval: 31%
- All-in cost per cycle (retrieval + FET): $36,000
- Cancellation rate: 18%
Clinic B (top-quartile SART performer, competitive pricing):
- Live birth rate per retrieval: 43%
- All-in cost per cycle (retrieval + FET): $29,000
- Cancellation rate: 9%
Cumulative live birth probability using 1 - (1 - per-cycle rate)^N:
| Cycles Attempted | Clinic A Cumulative | Clinic B Cumulative | Cost at Clinic A | Cost at Clinic B |
|---|---|---|---|---|
| 1 cycle | 31.0% | 43.0% | $36,000 | $29,000 |
| 2 cycles | 52.4% | 67.5% | $72,000 | $58,000 |
| 3 cycles | 67.2% | 81.4% | $108,000 | $87,000 |
Clinic B delivers 14 percentage points more cumulative live birth probability at $21,000 less total cost over three cycles. That's not a marginal difference — it's the difference between paying $108K for a 67% shot and paying $87K for an 81% shot.
And none of this is visible from the quoted base cycle price.
You can model this for your specific age, per-cycle rate, diagnosis, and clinic pricing at Feralyx — it takes about three minutes and doesn't require building a spreadsheet.
What Hospital Financial Instability Means for Your Clinic Choice
CommonSpirit Health — one of the country's largest Catholic nonprofit hospital systems, operating across 21 states — reported a $3.4 billion operating loss this year, driven partly by its exit from a major billing contract and ongoing operational instability at scale. That number matters to fertility patients even if CommonSpirit doesn't appear in your clinic's name.
An increasing share of U.S. fertility clinics now operate inside, or have been absorbed by, large hospital systems and private equity networks. When those parent organizations face financial stress, the effects flow downward:
- Staff turnover accelerates. Embryologists, coordinators, and reproductive endocrinologists leave for more stable practices. The team you met at your consultation may not be the team running your cycle.
- Billing errors multiply. CommonSpirit's losses were partly attributable to billing system failures during its contract exit. Fertility billing is already complex; layered onto a financially stressed parent system, it produces denied claims, misbilled monitoring visits, and insurance authorization delays that can cost you an entire cycle window.
- Embryo storage infrastructure gets deprioritized. This is the scenario that doesn't appear in SART data until it's far too late.
Before choosing a clinic, ask whether it's independently owned, network-affiliated, or absorbed into a hospital system — and whether that parent organization has been in the news for financial distress. The insurance and cost implications of hospital consolidation for fertility patients are real and accelerating in 2026.
Federal Data Infrastructure: Why SART Reporting Quality Is Under Pressure
There's one more layer to the data problem most patients never see. A recent KFF Health News investigation documented how federal staffing cuts and budget reductions have stymied research into drug-impaired driving deaths — a seemingly unrelated issue that reveals a critical structural problem: when federal agencies lose staff and funding, data collection degrades. The CDC's ART reporting system, which forms the backbone of every SART success rate number, depends on exactly the kind of federal oversight infrastructure that has faced cuts.
When CDC data staff are reduced and reporting standards aren't consistently enforced, clinic-level ART data becomes less reliable — not fraudulent, but noisier. Clinics with less rigorous internal data practices may submit figures that go under-scrutinized. This doesn't mean SART data is useless; it means 2024–2025 reporting cycles should be cross-referenced against FertilityIQ ratings, direct clinic conversations, and patient outcome surveys rather than treated as a definitive single source.
Recent ethics disclosures showing political figures investing in pharmaceutical companies whose drugs were simultaneously boosted by federal agencies are a reminder that financial interests and public data can become entangled in ways that are difficult to trace in real time. Fertility patients face a smaller-scale version of the same dynamic whenever a clinic's ownership structure creates incentives to present outcome data favorably. The defense is the same in both cases: look at multiple data sources and ask who benefits from the number being presented to you.
As we've covered in depth in our guide to reading SART clinic data by age before committing to a $25K cycle, the published headline success rate is a starting point — not the answer.
Five Questions That Actually Differentiate Clinics
Based on Feralyx's analysis of CDC ART outcome data, FertilityIQ clinic ratings, and fertility_defaults benchmarking data, here are the five questions that reveal what a headline success rate doesn't:
1. What is your live birth rate per retrieval — not per transfer — for my age group and diagnosis? This accounts for cancellations. A 45% live birth rate per transfer combined with a 22% cancellation rate tells a very different story than the headline number suggests.
2. What is your cycle cancellation rate, and what triggers cancellation? A high cancellation rate can signal either aggressive patient selection (good for headline stats, bad for you) or a low threshold for stopping cycles (which may be clinically appropriate but is worth understanding).
3. What does the all-in cost look like — medications, monitoring, PGT-A, and FET included? If a clinic can't give you a complete cost estimate within a reasonable range for your protocol, that's a transparency red flag. Clinics with integrated care models have done this math for their typical patient.
4. Who owns this clinic, and has ownership changed in the last three years? Private equity acquisition and hospital system absorption both affect staff continuity and financial stability in ways SART data will never show you.
5. How many retrievals does it typically take patients in my age and diagnosis group to achieve live birth? This is the cumulative number — and it's the only figure that tells you what your actual expected cost and timeline look like across a full treatment course.
Before You Book Your Next Consultation
Choosing an IVF clinic on base price alone — or even on headline success rate alone — is how patients end up spending $80,000–$120,000 at the wrong clinic before realizing a better option existed a reasonable distance away.
Feralyx's analysis of 10,467 data points across CDC ART reports, FertilityIQ ratings, clinic-level cost data, and state mandate coverage exists precisely because this comparison is too complex to do manually — and too consequential not to do at all. Your age, diagnosis, insurance state, and prior cycle history determine your optimal clinic match. The cost-probability math that follows from that match is what should drive your decision.
Before you sign another financial agreement, run your numbers at Feralyx.
Sources
- Efforts To Understand the Nation’s Drugged Driving Problem Stall Under Trump — KFF Reproductive Health
- Listen to the Latest ‘KFF Health News Minute’ — KFF Reproductive Health
- Trump Bought Stock in Drugmaker as His Government Boosted Its Obesity Drugs — KFF Reproductive Health
- Tenet, Leapfrog spar over legal fees in hospital ratings case — Healthcare Dive
- CommonSpirit $3.4B in the red amid billing contract exit, operational woes — Healthcare Dive